乳腺癌
抗体-药物偶联物
抗体
细胞毒性T细胞
曲妥珠单抗
药品
医学
肿瘤科
旁观者效应
人口
癌症
癌症研究
药理学
内科学
单克隆抗体
免疫学
生物
体外
环境卫生
生物化学
标识
DOI:10.1016/j.bbcan.2022.188849
摘要
The recent decade has witnessed a vigorous prosper of antibody-drug conjugates (ADCs) in solid tumors including breast cancer. Integrating the specificity of monoclonal antibodies and potency of cytotoxic drugs, ADCs are capable of delivering cytotoxic agents directly to tumor cells and surrounding accomplices with heterogeneous antigen expression by exerting the distinctive bystander effect. Up till now, three ADCs (T-DM1, T-DXd and SG) have attained the official approval and stepped into clinical practices in breast cancer, with numerous promising products in the pipeline. As an unprecedented breast cancer subgroup identified following solidified drug benefit, the cognitive and therapeutic paradigm of HER2-low population which was previously thought lacking definite targets and efficacious regimens has been thoroughly rewritten by ADCs, and several encouraging achievements are expected in ongoing trials. Herein, we discuss the contrived knowledge, latest advancements and future perspectives of ADCs in HER2-overexpressing and HER2-low breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI